验证数据展示
经过测试的应用
Positive IF/ICC detected in | HeLa cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL594-66170 targets RCAS1 in IF/ICC applications and shows reactivity with human samples.
经测试应用 | IF/ICC Application Description |
经测试反应性 | human |
免疫原 | RCAS1 fusion protein Ag2905 种属同源性预测 |
宿主/亚型 | Mouse / IgG1 |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | estrogen receptor binding site associated, antigen, 9 |
别名 | EB9, EBAG9, PDAF, RCAS1 |
计算分子量 | 213 aa, 24 kDa |
观测分子量 | 34 kDa |
GenBank蛋白编号 | BC017729 |
基因名称 | RCAS1 |
Gene ID (NCBI) | 9166 |
RRID | AB_3084702 |
偶联类型 | CoraLite®594 Fluorescent Dye |
最大激发/发射波长 | 588 nm / 604 nm |
形式 | Liquid |
纯化方式 | Protein G purification |
UNIPROT ID | O00559 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) gene was identified as an estrogen-responsive gene. The gene product, receptor-binding cancer antigen expressed on SiSo cells (RCAS1), is associated with aggressive characteristics and poor overall survival for 15 different human malignancies. The correlation between RCAS1 expression and several clinicopathological variables, including tumor size, clinical stage, invasion depth and lymph node metastasis highlights this molecule's clinical significance. Expression of RCAS1 in tumor cells plays an important role in evasion from host immune system resulting tumor progression, invasion and metastasis. Further exploration of RCAS1 biological function will facilitate development of novel therapeutic strategies that target RCAS1.
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL594 RCAS1 antibody CL594-66170 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |